The Association Between Immune-Related Conditions Across the Life-Course and Provoked Vulvodynia.


Journal

The journal of pain
ISSN: 1528-8447
Titre abrégé: J Pain
Pays: United States
ID NLM: 100898657

Informations de publication

Date de publication:
08 2023
Historique:
received: 08 11 2022
revised: 07 03 2023
accepted: 11 03 2023
pmc-release: 01 08 2024
medline: 21 8 2023
pubmed: 21 3 2023
entrez: 20 3 2023
Statut: ppublish

Résumé

Vulvodynia, impacts up to 8% of women by age 40, and is hypothesized to manifest through an altered immune-inflammatory response. To test this hypothesis, we identified all women born in Sweden between 1973 and 1996 diagnosed with localized provoked vulvodynia (N76.3) and/or vaginismus (N94.2 or F52.5) between 2001 and 2018. We matched each case to two women from the same birth year with no vulvar pain ICD codes. As a proxy for immune dysfunction, we used Swedish Registry data to capture 1) immunodeficiencies, 2) single organ and multiorgan autoimmune conditions, 3) allergy and atopies, and 4) malignancies involving immune cells across the life course. Women with vulvodynia, vaginismus or both were more likely to experience immune deficiencies (OR 1.8, 95% CI, 1.2-2.8), single organ (OR 1.4, 95% CI, 1.2-1.6) and/or multi-organ (OR 1.6, 95% CI, 1.3-1.9) immune disorders, and allergy/atopy conditions (OR 1.7, 95% CI, 1.6-1.8) compared to controls. We observed greater risk with increasing numbers of unique immune related conditions (1 code: OR = 1.6, 95% CI, 1.5-1.7; 2 codes: OR = 2.4, 95% CI, 2.1-2.9; 3 or more codes: OR = 2.9, 1.6-5.4). These findings suggest that women with vulvodynia may have a more compromised immune system either at birth or at points across the life course than women with no vulvar pain history. PERSPECTIVE: Women with vulvodynia are substantially more likely to experience a spectrum of immune related conditions across the life course. These findings lend support to the hypothesis that chronic inflammation initiates the hyperinnervation that causes the debilitating pain in women with vulvodynia.

Identifiants

pubmed: 36940787
pii: S1526-5900(23)00367-X
doi: 10.1016/j.jpain.2023.03.007
pmc: PMC10440273
mid: NIHMS1883963
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1415-1422

Subventions

Organisme : NICHD NIH HHS
ID : R21 HD099533
Pays : United States

Informations de copyright

Copyright © 2023 United States Association for the Study of Pain, Inc. Published by Elsevier Inc. All rights reserved.

Références

Semin Immunopathol. 2020 Aug;42(4):451-468
pubmed: 32661735
Am J Obstet Gynecol. 2015 Apr;212(4):476.e1-8
pubmed: 25448516
J Mol Med (Berl). 2018 Jun;96(6):537-545
pubmed: 29736603
Eur J Obstet Gynecol Reprod Biol. 2018 Jul;226:66-70
pubmed: 29852336
Trends Immunol. 2017 Jan;38(1):5-19
pubmed: 27793571
APMIS. 2015 May;123(5):452-6
pubmed: 25912132
Int J Equity Health. 2014 Nov 28;13:115
pubmed: 25431139
Sci Transl Med. 2011 Sep 21;3(101):101ra91
pubmed: 21937756
J Womens Health (Larchmt). 2021 Jun;30(6):799-806
pubmed: 33395559
Clin Epidemiol. 2021 Jul 19;13:533-554
pubmed: 34321928
Ann Epidemiol. 2009 Nov;19(11):771-7
pubmed: 19825458
J Am Med Womens Assoc (1972). 2003 Spring;58(2):82-8
pubmed: 12744420
J Low Genit Tract Dis. 2021 Oct 1;25(4):296-302
pubmed: 34542085
Gynecol Obstet Invest. 2004;58(3):171-8
pubmed: 15249746
BJOG. 2015 Feb;122(3):329-34
pubmed: 24990073
Front Mol Neurosci. 2019 Aug 06;12:186
pubmed: 31447644
Mol Immunol. 2015 Jan;63(1):38-44
pubmed: 24666768
Pain. 2015 Mar;156(3):386-396
pubmed: 25679469
Immunity. 2017 Jun 20;46(6):927-942
pubmed: 28636960
Eur J Epidemiol. 2023 Jan;38(1):109-120
pubmed: 36595114
J Reprod Med. 2009 Jun;54(6):385-92
pubmed: 19639929
Am J Obstet Gynecol. 2016 Dec;215(6):768.e1-768.e8
pubmed: 27457118
Am J Obstet Gynecol. 2014 Jan;210(1):40.e1-8
pubmed: 24080300
J Clin Invest. 2019 Mar 4;129(4):1475-1482
pubmed: 30829650
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
J Womens Health (Larchmt). 2017 Oct;26(10):1069-1076
pubmed: 28686502

Auteurs

Bernard L Harlow (BL)

Department of Epidemiology, Boston University School of Public Health. Boston, Massachusetts. Electronic address: harlow@bu.edu.

Chad M Coleman (CM)

Department of Epidemiology, Boston University School of Public Health. Boston, Massachusetts.

Hanna Mühlrad (H)

Department of Clinical Sciences, Division of Obstetrics and Gynecology, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden; The Institute for Evaluation of Labor Market and Education Policy (IFAU), Uppsala, Sweden.

Jacinth Yan (J)

Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

Evelina Linnros (E)

Institute for International Economic Studies, Stockholm University, Stockholm, Sweden.

Donghao Lu (D)

Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

Matthew P Fox (MP)

Department of Epidemiology, Boston University School of Public Health. Boston, Massachusetts; Department of Global Health, Boston University School of Public Health, Boston, Massachusetts.

Nina Bohm-Starke (N)

Department of Clinical Sciences, Division of Obstetrics and Gynecology, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH